2016 Q3 Form 10-Q Financial Statement
#000143774916041929 Filed on November 14, 2016
Income Statement
| Concept | 2016 Q3 | 2015 Q3 |
|---|---|---|
| Revenue | $440.1K | $93.13K |
| YoY Change | 372.57% | -71.09% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $220.0K | $340.0K |
| YoY Change | -35.29% | -17.07% |
| % of Gross Profit | ||
| Research & Development | $683.9K | $378.5K |
| YoY Change | 80.69% | -11.04% |
| % of Gross Profit | ||
| Depreciation & Amortization | $10.00K | $10.00K |
| YoY Change | 0.0% | -50.0% |
| % of Gross Profit | ||
| Operating Expenses | $904.6K | $714.5K |
| YoY Change | 26.62% | -14.67% |
| Operating Profit | -$464.5K | -$621.3K |
| YoY Change | -25.23% | 20.59% |
| Interest Expense | $0.00 | $0.00 |
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $340.00 | $1.424K |
| YoY Change | -76.12% | 100.28% |
| Pretax Income | -$460.0K | -$620.0K |
| YoY Change | -25.81% | 21.57% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$464.2K | -$619.9K |
| YoY Change | -25.12% | 20.48% |
| Net Earnings / Revenue | -105.47% | -665.63% |
| Basic Earnings Per Share | -$0.02 | |
| Diluted Earnings Per Share | -$209.5B | -$388.0B |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q3 | 2015 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $510.0K | $1.820M |
| YoY Change | -71.98% | 111.63% |
| Cash & Equivalents | $511.1K | $1.821M |
| Short-Term Investments | ||
| Other Short-Term Assets | $80.00K | $80.00K |
| YoY Change | 0.0% | 33.33% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $10.00K | $0.00 |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $602.2K | $1.896M |
| YoY Change | -68.25% | 104.7% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $62.02K | $90.84K |
| YoY Change | -31.72% | -19.77% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $10.00K | $10.00K |
| YoY Change | 0.0% | -25.98% |
| Total Long-Term Assets | $73.03K | $101.9K |
| YoY Change | -28.29% | -19.64% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $602.2K | $1.896M |
| Total Long-Term Assets | $73.03K | $101.9K |
| Total Assets | $675.2K | $1.998M |
| YoY Change | -66.21% | 89.74% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $33.50K | $42.49K |
| YoY Change | -21.17% | -48.3% |
| Accrued Expenses | $219.1K | $5.000K |
| YoY Change | 4281.84% | -39.61% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $252.6K | $118.2K |
| YoY Change | 113.66% | -30.55% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $252.6K | $118.2K |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $250.0K | $120.0K |
| YoY Change | 108.33% | -29.41% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$34.81M | -$31.78M |
| YoY Change | 9.53% | |
| Common Stock | $34.22M | $32.60M |
| YoY Change | 4.95% | 12.85% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $422.6K | $1.880M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $675.2K | $1.998M |
| YoY Change | -66.21% | 89.74% |
Cashflow Statement
| Concept | 2016 Q3 | 2015 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$464.2K | -$619.9K |
| YoY Change | -25.12% | 20.48% |
| Depreciation, Depletion And Amortization | $10.00K | $10.00K |
| YoY Change | 0.0% | -50.0% |
| Cash From Operating Activities | -$410.0K | -$650.0K |
| YoY Change | -36.92% | 32.65% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 700.0K | 0.000 |
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -410.0K | -650.0K |
| Cash From Investing Activities | 0.000 | 0.000 |
| Cash From Financing Activities | 700.0K | 0.000 |
| Net Change In Cash | 290.0K | -650.0K |
| YoY Change | -144.62% | 25.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$410.0K | -$650.0K |
| Capital Expenditures | $0.00 | $0.00 |
| Free Cash Flow | -$410.0K | -$650.0K |
| YoY Change | -36.92% | 41.3% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q3 | govx |
Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
|
57969 | |
| CY2015Q4 | govx |
Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
|
||
| govx |
Class Of Warrant Or Right Exchanged During Period Exercise Price
ClassOfWarrantOrRightExchangedDuringPeriodExercisePrice
|
0.065 | ||
| CY2016Q3 | govx |
Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
|
38568159 | |
| CY2016Q3 | govx |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable
|
0.16 | |
| govx |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
-15821920 | ||
| govx |
Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
|
7350000 | ||
| CY2016Q3 | govx |
Unused Grant Funds
UnusedGrantFunds
|
680419 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
31950813 | |
| CY2016Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
49173 | |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
31951 | |
| CY2016Q3 | us-gaap |
Deposits Assets
DepositsAssets
|
11010 | |
| CY2015Q4 | us-gaap |
Deposits Assets
DepositsAssets
|
11010 | |
| CY2016Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
219092 | |
| CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
26055 | |
| CY2016Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
126123 | |
| CY2016Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
33497 | |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
100935 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2016Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
49172733 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31950813 | |
| CY2016Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
49172733 | |
| us-gaap |
Revenue From Grants
RevenueFromGrants
|
268028 | ||
| CY2015Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1305 | |
| CY2016Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
608223 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
586638 | |
| CY2016Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
34167870 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
32587543 | |
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
758636 | ||
| us-gaap |
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
51983 | ||
| CY2016Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
28716 | |
| CY2015Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
16926 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
525887 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
50516 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
73100000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
79000000 | ||
| CY2016Q3 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
8400 | |
| CY2016Q3 | us-gaap |
Assets
Assets
|
675191 | |
| CY2015Q4 | us-gaap |
Assets
Assets
|
1331593 | |
| CY2016Q3 | us-gaap |
Assets Current
AssetsCurrent
|
602158 | |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1236975 | |
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2. Basis of Presentation</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying condensed consolidated financial statements at September 30, 2016 and for the three-month and nine-month periods ended September 30, 2016 and 2015 are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Certain prior year amounts have been reclassified to conform to the current year presentation. Interim results are not necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015. We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations into the first quarter of 2017. Due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through additional government grants and contracts. We also intend to secure additional funds through sales of our equity securities or the exercise of currently outstanding stock purchase warrants. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the substantial doubt about the Company’s ability to operate as a going concern. Additional funding may not be available on favorable terms or at all. If we fail to obtain additional capital when needed, we will be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.</div></div></div> | ||
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1060348 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1101651 | |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
511096 | |
| CY2015Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1821037 | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-549252 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
719386 | ||
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.14 | |
| CY2016Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.16 | |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
56442157 | |
| CY2016Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
40620237 | |
| CY2016Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
76089142 | |
| CY2016Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-15850 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-2336314 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1577678 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1944573 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
21585 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
21701 | ||
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.01 | |
| CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.02 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | ||
| CY2016Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
54286 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1Y255D | ||
| CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
220707 | |
| CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
335932 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1472030 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1102262 | ||
| CY2016Q3 | us-gaap |
Grants Receivable
GrantsReceivable
|
8765 | |
| CY2015Q4 | us-gaap |
Grants Receivable
GrantsReceivable
|
119978 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
125599 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-68802 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
25648 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
30773 | ||
| us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-111213 | ||
| us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-79341 | ||
| CY2016Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
340 | |
| CY2015Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1424 | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1249 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4481 | ||
| CY2016Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
675191 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1331593 | |
| CY2016Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
252589 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
126990 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1. Description of Business </div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on Human Immunodeficiency Virus (HIV), hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), Zika virus, and cancer immunotherapy. We also recently began a program to develop a therapeutic vaccine for chronic Hepatitis B infections. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our HIV vaccine technology was developed in collaboration with Emory University, the National Institutes of Health (NIH), and the</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Centers for Disease Control and Prevention (CDC) and is exclusively licensed to us. We also have nonexclusive licenses to certain patents owned by the NIH, and are developing our hemorrhagic fever and Zika vaccines, and our cancer immunotherapy program with technology we expect to license from the NIH.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area). </div></div></div> | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1028426 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2679809 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
|||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2337563 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2001037 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-1996556 | ||
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-464200 | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-619899 | |
| CY2016Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
340 | |
| CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1424 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1249 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
4481 | ||
| CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
904646 | |
| CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
714453 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
2991549 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
2269065 | ||
| CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-464540 | |
| CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-621323 | |
| CY2016Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
189254 | |
| CY2016Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
151993 | |
| CY2016Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
37261 | |
| CY2016Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
35000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
24750 | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
|||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
15850 | ||
| CY2016Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2016Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2016Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
82297 | |
| CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
56649 | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1028426 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
|||
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
|||
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
2679809 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
477750 | ||
| CY2016Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
670246 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
670246 | |
| CY2016Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
62023 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
83608 | |
| CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
683939 | |
| CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
378521 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1519519 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1166803 | ||
| CY2016Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-34811241 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-32474927 | |
| CY2016Q3 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
440106 | |
| CY2015Q3 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
93130 | |
| us-gaap |
Revenue From Grants
RevenueFromGrants
|
653986 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
|||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
|||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
525887 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
50516 | ||
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
923061 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
4.31 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
|||
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1705500 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1705500 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.41 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.41 | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
|||
| CY2016Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
422602 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1204603 | |
| CY2016Q3 | us-gaap |
Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
|
305000 | |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44305161 | |
| CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31950813 | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38796869 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31950813 |
